Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 33

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 33
---
 with the termination of such party’s employment with us pursuant to contractual agreements with us, provided that no public disclosure or filing under Section 16(a) of the Exchange Act shall be voluntarily made during the restricted period and, if required, any public disclosure or filing under Section 16(a) of the Exchange Act shall indicate in the footnotes thereto the nature of the transaction (it being understood that such party may make required filings on Schedule 13D, Schedule 13F, Schedule 13G and any amendments thereto during the restricted period);

(f)

the issuance and sale of shares of Class A common stock pursuant to the Equity Distribution Agreement, dated August 13, 2025, by and between us and Piper Sandler & Co, as sales agent relating to the Company’s at-the-market sales program, following the 30-day period commencing as of the date hereof; provided that such shares of Common Stock are sold at a price per share not less than the public offering price;

(g)

the issuance and sale of the securities in the concurrent private placement;

(h)

the establishment of a trading plan on behalf of one of our shareholders, officers or directors pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of our common stock,

<div align='center'>S-24</div>

TABLE OF CONTENTS

provided that (i) such plan does not provide for the transfer of our common stock during the restricted period and (ii) to the extent a public announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of such party or us regarding the establishment of such plan, such announcement or filing shall include a statement to the effect that no transfer of our common stock may be made under such plan during the restricted period; or

(i)

transfers pursuant to a bona fide third-party tender offer for all outstanding shares of our common stock, merger, consolidation or other similar transaction made to all holders of our securities involving a change of control of us and approved by our board of directors (including, without limitation, the entering into any lock-up, voting or similar agreement pursuant to which such party may agree to transfer, sell, tender or otherwise dispose of our common stock or other such securities in connection with such transaction, or vote any shares of our common stock or other such securities in favor of any such transaction); provided that in the event that such tender offer, merger, consolidation or other such transaction is not completed, such securities held by such